{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step": "Step 1: Disease Mechanism Defined",
          "details": "The paper defines α-syn membrane binding and solubility as critical to PD pathogenesis (via Lewy body formation). Mutant A30P impairs membrane binding, which disrupts normal α-syn function."
        },
        {
          "step": "Step 2: Assay Relevance",
          "details": "The study uses co-incubation with brain cytosol and tests lipid/ATP effects on membrane binding. These assays directly assess α-syn's functional property (membrane binding), which is central to the disease mechanism."
        },
        {
          "step": "Step 3: Assay Validity",
          "details": [
            {
              "substep": "3a: Controls and Replicates",
              "details": "Wild-type and mutant A30P α-syn are compared. The paper does not explicitly state replicate counts, but controls (cytosol vs. no cytosol) are present."
            },
            {
              "substep": "3c: Variant Controls",
              "details": "A30P is compared to wild-type α-syn. Since A30P is a known pathogenic variant, it serves as a positive control."
            }
          ]
        },
        {
          "step": "Step 4: Statistical Evidence",
          "details": [
            {
              "substep": "4b: No OddsPath Calculation",
              "details": "The paper does not report statistical metrics (p-values, OddsPath). Total control variants (A30P, A53T, E46K) are 3. With ≤10 total controls, evidence strength is capped at PS3_supporting."
            }
          ]
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step": "Step 1: Disease Mechanism Defined",
          "details": "The paper defines α-syn membrane binding and solubility as critical to PD pathogenesis. Mutant A53T is modulated by cytosolic factors (lipids/ATP), altering its functional behavior."
        },
        {
          "step": "Step 2: Assay Relevance",
          "details": "The study uses co-incubation with brain cytosol and tests lipid/ATP effects on membrane binding. These assays directly assess α-syn's functional property (membrane binding), which is central to the disease mechanism."
        },
        {
          "step": "Step 3: Assay Validity",
          "details": [
            {
              "substep": "3a: Controls and Replicates",
              "details": "Wild-type and mutant A53T α-syn are compared. The paper does not explicitly state replicate counts, but controls (cytosol vs. no cytosol) are present."
            },
            {
              "substep": "3c: Variant Controls",
              "details": "A53T is compared to wild-type α-syn. Since A53T is a known pathogenic variant, it serves as a positive control."
            }
          ]
        },
        {
          "step": "Step 4: Statistical Evidence",
          "details": [
            {
              "substep": "4b: No OddsPath Calculation",
              "details": "The paper does not report statistical metrics (p-values, OddsPath). Total control variants (A30P, A53T, E46K) are 3. With ≤10 total controls, evidence strength is capped at PS3_supporting."
            }
          ]
        }
      ],
      "final_strength": "PS3_supporting"
    }
  ]
}